Deutsch English Français

Contact

EP1836225

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1836225

EP1836225 - KIR-BINDING AGENTS AND METHODS OF USE THEREOF [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 07.09.2012 Database last updated on 28.09.2024
Most recent event Tooltip	07.09.2012	No opposition filed within time limit	published on 10.10.2012 [2012/41]
Applicant(s)	For all designated states NOVO NORDISK A/S Novo Allé 2880 Bagsvaerd / DK
	For all designated states Innate Pharma S.A.S. Immeuble Grand Pré 121, Ancien Chemin de Cassis 13009 Marseille / FR
	[N/P]
Former [2011/44]	For all designated states NOVO NORDISK A/S Novo Allé 2880 Bagsvaerd / DK
	For all designated states Innate Pharma Immeuble Grand Pré 121, ancien Chemin de Cassis 13009 Marseille / FR
Former [2007/39]	For all designated states NOVO NORDISK A/S Novo Allé 2880 Bagsvaerd / DK
	For all designated states Innate Pharma S.A.S. Immeuble Grand Pré 121, ancien Chemin de Cassis 13009 Marseille / FR
Inventor(s)	01 / PADKÆR, Søren, Berg Rosen Allé 2 Hareskov DK-3500 Værløse / DK
	02 / WAGTMANN, Peter, Andreas, Nicolai, Reumert Vallerød Banevej 34 DK-2960 Rungsted Kyst / DK
	03 / SPEE, Pieter Orchidévej 12 DK-3450 Allerød / DK
	04 / ZAHN, Stefan Byager 23 DK-2750 Ballerup / DK
	05 / KJæRGAARD, Kristian Buestræde 7 DK-2750 Ballerup / DK
	06 / Svensson, Anders Roskildevägen 17B S-217 46 Malmö / SE
	[2011/44]
Former [2008/51]	01 / PADKÆR, Søren, Berg Rosen Allé 2, Hareskov DK-3500 Værløse / DK
	02 / WAGTMANN, Peter, Andreas, Nicolai, Reumert Vallerød Banevej 34 DK-2960 Rungsted Kyst / DK
	03 / SPEE, Pieter Orchidévej 12 DK-3450 Allerød / DK
	04 / ZAHN, Stefan Byager 23 DK-2750 Ballerup / DK
	05 / KJæRGAARD, Kristian Buestræde 7 DK-2750 Ballerup / DK
	06 / Svensson, Anders Roskildevägen 17B S-217 46 Malmö / SE
Former [2007/39]	01 / PADKÆR, Søren, Berg Rosen Allé 2, Hareskov DK-3500 Værløse / DK
	02 / WAGTMANN, Peter, Andreas, Nicolai, Reumert Vallerød Banevej 34 DK-2960 Rungsted Kyst / DK
	03 / SPEE, Pieter Orchidévej 12 DK-3450 Allerød / DK
	04 / ZAHN, Stefan Byager 23 DK-2750 Ballerup / DK
	05 / KJæRGAARD, Kristian Buestræde 7 DK-2750 Ballerup / DK
Representative(s)	Gallois, Valérie, et al Cabinet BECKER & ASSOCIES 25, rue Louis Le Grand 75002 Paris / FR
	[N/P]
Former [2009/27]	Gallois, Valérie, et al Cabinet BECKER & ASSOCIES 25, rue Louis Le Grand 75002 Paris / FR
Former [2007/39]	Nilsson, Karin Norvin Novo Nordisk A/S Corporate Patents Novo Allé DK-2880 Bagsvaerd / DK
Application number, filing date	06701729.3	06.01.2006
	[2007/39]
	WO2006EP50073
Priority number, date	DK20050000021	06.01.2005 Original published format: DK 200500021
	[2007/39]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2006072626
	Date:	13.07.2006
	Language:	EN
	[2006/28]
	Type:	A1 Application with search report
	No.:	EP1836225
	Date:	26.09.2007
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 13.07.2006 takes the place of the publication of the European patent application.
	[2007/39]
	Type:	B1 Patent specification
	No.:	EP1836225
	Date:	02.11.2011
	Language:	EN
	[2011/44]
Search report(s)	International search report - published on:	EP	13.07.2006
Classification	IPC:	C07K16/28, A61K39/395, A61P35/00, A61P31/00, A61P37/00, C12N5/12, C12N15/13	[2007/39]
	CPC:	C07K16/2803 (EP,US); A61P31/00 (EP); A61P31/12 (EP); A61P31/14 (EP); A61P31/18 (EP); A61P35/00 (EP); (+) A61P35/02 (EP); A61P37/00 (EP); A61P43/00 (EP); C07K16/28 (US); C07K2299/00 (EP,US); C07K2317/55 (EP,US); C07K2317/73 (EP,US); C07K2317/76 (US) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2007/39]
Title	German:	KIR-BINDENDE WIRKSTOFFE UND VERFAHREN ZU IHRER VERWENDUNG	[2007/39]
	English:	KIR-BINDING AGENTS AND METHODS OF USE THEREOF	[2007/39]
	French:	AGENTS DE LIAISON KIR ET LEURS PROCEDES D'UTILISATION	[2007/39]
Entry into regional phase	06.08.2007	National basic fee paid
	06.08.2007	Designation fee(s) paid
	06.08.2007	Examination fee paid
Examination procedure	06.08.2007	Examination requested [2007/39]
	08.02.2008	Despatch of a communication from the examining division (Time limit: M06)
	01.12.2008	Reply to a communication from the examining division
	14.05.2009	Despatch of a communication from the examining division (Time limit: M06)
	08.01.2010	Reply to a communication from the examining division
	11.01.2010	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	24.06.2010	Despatch of a communication from the examining division (Time limit: M04)
	21.10.2010	Reply to a communication from the examining division
	04.05.2011	Communication of intention to grant the patent
	30.08.2011	Fee for grant paid
	30.08.2011	Fee for publishing/printing paid
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 08.02.2008
Opposition(s)	03.08.2012	No opposition filed within time limit [2012/41]
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	01.12.2008	Request for further processing filed
	01.12.2008	Full payment received (date of receipt of payment) Request granted
	17.12.2008	Decision despatched
Fees paid	Renewal fee
	31.01.2008	Renewal fee patent year 03
	14.01.2009	Renewal fee patent year 04
	13.01.2010	Renewal fee patent year 05
	14.01.2011	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[E]WO2006003179 (NOVO NORDISK AS [DK], et al) [E] 1-55* the whole document *;
		[X] - MORETTA A ET AL, "A NOVEL SURFACE ANTIGEN EXPRESSED BY A SUBSET OF HUMAN CD3-MINUS CD16-POSITIVE NATURAL KILLER CELLS ROLE IN CELL ACTIVATION AND REGULATION OF CYTOLYTIC FUNCTION", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, (199003), vol. 171, no. 3, ISSN 0022-1007, pages 695 - 714, XP002309351 [X] 1-11,13-15,19,21,40,42-45,48,49 * the whole document * DOI: http://dx.doi.org/10.1084/jem.171.3.695
		[X] - V. PASCAL ET AL, "Comparative analysis of NO cell subset distribution in normal and lymphoproliferative disease of granular lymphocyte conditions", EUR. J. IMMUNOL., (2004), vol. 34, pages 2930 - 2940, XP002374947 [X] 1-11,13-15,19,21,44,45,48,49 * See Materials and methods (antibodies) * DOI: http://dx.doi.org/10.1002/eji.200425146
		[X] - G. DOROTHEE ET AL, "Functional and molecular characterization of a KIR3DL2/p140 expressing tumor-specific cytotoxic T lymphocyte clone infiltrating a human lung carcinoma", ONCOGENE, (2003), vol. 22, pages 7192 - 7198, XP002374948 [X] 1-11,13-15,19,21,44,45,48,49 * See Materials and methods (mAbs and immunofluorescence analysis) * DOI: http://dx.doi.org/10.1038/sj.onc.1206627
		[X] - P.K. EPLING-BURNETTE ET AL, "Dysregulated NL receptor expression in patients with lymphoproliferative disease of granular lymphocytes", BLOOD, (2004), vol. 103, no. 9, pages 3431 - 3439, XP002374949 [X] 1-11,13-15,19,21,44,45,48,49 * See paragraph Patients, material and methods (Surface phenotyping by flow cytometry) * DOI: http://dx.doi.org/10.1182/blood-2003-02-0400
		[X] - N. LEE ET AL, "HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A", PROC. NATL. ACAD. SCI., (1998), vol. 95, pages 5199 - 5204, XP002374950 [X] 1-11,13-15,19,21,44,45,48,49 * See Materials and methods (antibodies and antisera) * DOI: http://dx.doi.org/10.1073/pnas.95.9.5199
		[X] - SHIN J-S ET AL, "MONOCLONAL ANTIBODIES WITH VARIOUS REACTIVITY TO P58 KILLER INHIBITORY RECEPTORS", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, (199912), vol. 18, no. 6, ISSN 0272-457X, pages 521 - 527, XP001041418 [X] 1-19,21,44,45,48,49 * See Materials and methods (table I) *
		[X] - C. WATZL ET AL, "Homogeneous expression of killer cell immunoglobulin-like receptors (KIR) on polyclonal natural killer cells detected by a monoclonal antibody to KIR2D", TISSUE ANTIGENS, (2000), vol. 56, pages 240 - 247, XP002374951 [X] 1-11,13-15,19,21,44,45,48,49 * See Materials and methods (antibodies) * DOI: http://dx.doi.org/10.1034/j.1399-0039.2000.560306.x
		[X] - N. WAGTMANN ET AL, "Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer", IMMUNITY, (1995), vol. 3, pages 801 - 809, XP002374952 [X] 1-11,13-15,19,21,44,45,48,49 * See experimental procedures (cells and antibodies) * DOI: http://dx.doi.org/10.1016/1074-7613(95)90069-1
	Examination	- PASCAL V. ET AL, "Detection of KIR3DS1 on the cell surface of peripheral blood NK cells facilitates identification of a novel null allele and assessment of KIR3DS1 expression during HIV-1 infection", JOURNAL OF IMMUNOLOGY, (2007), vol. 179, no. 3, pages 1625 - 1633
		- THANANCHAI HATHAIRAT, "Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B", JOURNAL OF IMMUNOLOGY, (2007), vol. 178, no. 1, pages 33 - 37
		- THOMAS R, ET AL, "Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation?", JOURNAL OF IMMUNOLOGY, (2008), vol. 180, no. 10, pages 6743 - 6760
		- LI H. ET AL, "Genetic control of variegated KIR gene expression : polymorphisms of the bi-directional KIRDL1 promoter are associated with distinct frequencies of gene expression", PLOS GENETICS, (2008), vol. 4, no. 11, pages 1 - 11
		- PASCAL V. ET AL, "Detection of KIR3DS1 on the cell surface of peripheral blood NK cells facilitates identification of a novel Null allel and seessmenet of KIR3DS1 expression during HIV -1 infection", THE JOURNAL OF IMMUNOLOGY, (2007), vol. 179, pages 1625 - 1633
		- THANACHAI H. ET AL, "Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B", THE JOURNAL OF IMMUNOLOGY, vol. 178, pages 33 - 37
		- LI H. ET AL, "Genetic control ogf variegated KIR gene expression: polymorphisms of the bi-directional KIR3Dl1 promoter are associated with distinct frequencies of gene expression", PLOS GENETICS, (2008), vol. 4, no. 1, pages 1 - 11
	by applicant	US4816397
		US4816567
		WO9849292
		US5916771
		WO0002583
		WO0050081
		US6162963
		WO03040170
		US2003095965
		WO03064606
		WO2005003172
		WO2005003168
		WO2005009465
		WO2005060375
		- LANIER, ANNUAL REVIEW OF IMMUNOLOGY, (2005), vol. 23, pages 225 - 74
		- KARRE ET AL., NATURE, (1986), vol. 319, pages 675 - 8
		- OHIEN ET AL., SCIENCE, (1989), vol. 246, pages 666 - 8
		- FAURE ET AL., J IMMUNOL, (2003), vol. 170, pages 6107 - 6114
		- FAN ET AL., J. BIOL. CHEM., (2000), vol. 98, page 1734
		- MORETTA ET AL., EUR J IMMUNOGENET., (1997), vol. 24, no. 6, pages 455 - 68
		- VALIANTE ET AL., IMMUNOL REV, (1997), vol. 155, pages 155 - 64
		- LANIER, ANNU REV IMMUNOL, (1998), vol. 16, pages 359 - 93
		- RUGGERI ET AL., SCIENCE, (2002), vol. 295, pages 2097 - 2100
		- WARD ET AL., NATURE, (1989), vol. 341, pages 544 - 546
		- BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426
		- HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883
		- M. CARRINGTON; P. NORMAN, THE KIR GENE CLUSTER
		- PEARSON, METHODS ENZYMOL., (1990), vol. 183, pages 63 - 98
		- PEARSON, METHODS MOL. BIOL., (2000), vol. 132, pages 185 - 219
		- LITWIN ET AL., JOUR NAL OF EXPERIMENTAL MEDICINE, (1993), vol. 178, pages 1321 - 1336
		- WAGTMANN ET AL., IMMUNITY, (1995), vol. 3, pages 801 - 809
		- EHRING H, ANALYTICAL BIOCHEMISTRY, (1999), vol. 267, no. 2, pages 252 - 259
		- ENGEN, J.R.; SMITH, D.L., ANAL. CHEM., (2001), vol. 73, pages 256A - 265A
		- ERNST SCHERING RES FOUND WORKSHOP, (2004), no. 44, pages 149 - 67
		- HUANG ET AL., JOURNAL OF MOLECULAR BIOLOGY, (1998), vol. 281, no. 1, pages 61 - 67
		- SAITO; PATTERSON, METHODS, (199606), vol. 9, no. 3, pages 516 - 24
		- DOWNWARD, J MASS SPECTROM., (200004), vol. 35, no. 4, pages 493 - 503
		- KISELAR; DOWNARD, ANAL CHEM., (19990501), vol. 71, no. 9, pages 1792 - 801
		- MANCA, ANN IST SUPER SANITA, (1991), vol. 27, no. 1, pages 15 - 9
		- SOL MA; PAZOS F; VALENCIA A, J. MOL. BIOL., (2003), vol. 326, pages 1289 - 1302
		- SCHNEIDMAN-DUHOVNY D; NUSSINOV R; WOLFSON HJ, CURR. MED. CHEM., (2004), vol. 11, pages 91 - 107
		- GODING, Monoclonal Antibodies: Principles and Practice, ACADEMIC PRESS, (1986), pages 59 - 103
		- SKERRA ET AL., CURR. OPINION IN IMMUNOL., (1993), vol. 5, page 256
		- PLUCKTHUN, IMMUNOL. REVS., (1992), vol. 130, page 151
		- WARD ET AL., NATURE, (1989), vol. 341, page 544
		- MORRISON ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1984), vol. 81, page 6851
		- RUKER ET AL., ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1991), vol. 646, pages 212 - 219
		- BIANCHI ET AL., BIOTECHNOLOGY AND BIOENGINEERING, (2003), vol. 84, pages 439 - 444
		- SOO KIM ET AL., BIO- TECHNOL. PROG., (2001), vol. 17, pages 69 - 75
		- KING ET AL., BIOCHEMICAL JOURNAL, (1992), vol. 281, pages 317 - 323
		- JONES ET AL., NATURE, (1986), vol. 321, page 522
		- REICHMANN ET AL., NATURE, (1988), vol. 332, page 323
		- PRESTA, CURR. OP. STRUCT. BIOL., (1992), vol. 2, page 593
		- RIECHMANN ET AL., NATURE, (1988), vol. 332, page 323
		- VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, page 1534
		- SIMS ET AL., J. IMMUNOL., (1993), vol. 151, page 2296
		- CHOTHIA; LESK, J. MOL. BIOL., (1987), vol. 196, page 901
		- CARTER ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1992), vol. 89, page 4285
		- PRESTA ET AL., J. IMMUNOL., (1993), vol. 51
		- JAKOBOVITZ ET AL., NATURE, (1993), vol. 362, page 255
		- WILLIAMS; POLLI, J. PARENTERAL SCI. TECHNOL., (1984), vol. 38, pages 48 - 59
		- MASTERS, Spray-Drying Handbook, LONGMAN SCIENTIFIC AND TECHNICAL, (1991), pages 491 - 676
		- BROADHEAD ET AL., DRUG DEVEL. IND. PHARM., (1992), vol. 18, pages 1169 - 1206
		- MUMENTHALER ET AL., PHARM. RES., (1994), vol. 11, pages 12 - 20
	- CARPENTER; CROWE, CRYOBIOLOGY, (1988), vol. 25, pages 459 - 470
	- ROSER, BIOPHARM., (1991), vol. 4, pages 47 - 53
	- "Handbook of Pharmaceutical Controlled Release", Drug and the Pharmaceutical Sciences, MARCEL DEKKER, (2000), vol. 99
	- YU J; HIEN YW, "Pulmonary drug delivery: Physiologic and mechanistic aspects", CRIT REV THER DRUG CARR SYS, (1997), vol. 14, no. 4, pages 395 - 453
	- EDWARDS DA; BEN-JEBRIA A; LANGER R., "Recent advances in pulmonary drug delivery using large, porous inhaled particles", J APPL PHYSIOL, (1998), vol. 84, no. 2, pages 379 - 385
	- EDWARDS DA; BEN-JEBRIA A; LANGER R, "Recent advances in pulmonary drug delivery using large, porous inhaled particles", J APPL PHYSIOL, (1998), vol. 84, no. 2, pages 379 - 385
	- EDWARDS DA; BEN-JEBRIA A; LANGER A, "Recent advances in pulmonary drug delivery using large, porous inhaled particles", J APPL PHYSIOL, (1998), vol. 84, no. 2, pages 379 - 385
	- FAN ET AL., NATURE, (1997), vol. 389, pages 96 - 100
	- MITRA ET AL., CURRENT BIOLOGY, (2004), vol. 14, pages 718 - 724
	- H.M. BERMAN; J. WESTBROOK; Z. FENG; G. GILLILAND; T.N. BHAT; H. WEISSIG; I.N. SHINDYALOV; P.E. BOURNE, "The Protein Data Bank", NUCLEIC ACIDS RESEARCH, (2000), vol. 28, pages 235 - 242
	- KABSCH, J., APPL. CRYSTALLOGR., (1993), vol. 26, pages 795 - 800
	- BAILEY, ACTA CRYSTALLOGR. SECT. D-BIOL. CRYSTALLOGR., (1994), vol. 50, pages 760 - 763
	- LAMZIN; WILSON, "Acta Crystallogr", SECT. D-BIOL. CRYSTALLOGR., (1993), vol. 49, pages 129 - 147
	- WAGTMANN ET AL., IMMUNITY, (1995), vol. 3, no. 6, pages 801 - 9
	- LITWIN ET AL., J EXP MED., (1993), vol. 178, pages 1321 - 36

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p